Published in J Clin Oncol on August 11, 2014
Molecular radiobiology: the state of the art. J Clin Oncol (2014) 0.96
Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol (2015) 0.95
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int J Mol Sci (2016) 0.91
Enhancing the efficacy of radiation therapy: premises, promises, and practicality. J Clin Oncol (2014) 0.81
STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers. Oncotarget (2016) 0.80
The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. Oncologist (2016) 0.79
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther (2015) 0.79
Radiation oncology: a snapshot in time, 2014. J Clin Oncol (2014) 0.79
MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget (2016) 0.79
Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett (2016) 0.78
Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget (2015) 0.78
External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma. Expert Rev Anticancer Ther (2016) 0.78
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol (2014) 0.76
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget (2017) 0.75
Blood-brain barrier crossing and breakthroughs in glioblastoma therapy. Br J Clin Pharmacol (2016) 0.75
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun (2016) 0.75
Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. Ther Adv Med Oncol (2016) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A (1983) 5.00
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res (1999) 2.71
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res (2000) 2.56
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol (2009) 2.53
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol (2013) 2.22
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 1.87
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol (2012) 1.84
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm (1999) 1.49
Personalizing oncology: perspectives and prospects. J Clin Oncol (2013) 1.42
National Institutes of Health funding in radiation oncology: a snapshot. Int J Radiat Oncol Biol Phys (2013) 1.42
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol (2009) 1.33
Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol (2008) 1.23
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep (2012) 1.16
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res (2010) 1.08
The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective. Int J Radiat Oncol Biol Phys (2012) 1.07
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys (2012) 1.06
Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev (2011) 1.04
Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res (2009) 1.03
Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol (2007) 1.03
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer (2012) 1.02
Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys (1979) 1.02
Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes. J Natl Compr Canc Netw (2012) 1.01
Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat (2012) 0.95
Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys (2009) 0.95
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol (2012) 0.94
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 0.91
Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.87
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer (2010) 0.86
The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer (2010) 0.83
Targeted therapies with chemoradiation in esophageal cancer: development and future directions. Semin Radiat Oncol (2013) 0.83
Strategizing the clone wars: pharmacological control of cellular sensitivity to radiation. Mol Interv (2010) 0.77